Trials / Completed
CompletedNCT03565341
Efficacy and Safety of PiQo4 Device for Treatment of Melasma
Evaluation of the Efficacy and Safety of the PiQo4 Picosecond Laser (PSL) System for the Treatment of Patients With Melasma: A Prospective, Randomized, Split Face Study Comparing the Added Value of 585nm Over 1064nm PSL
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Focus Medical, LLC · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
Single center, Prospective, Open Label with Split-face Study Design. Face sides will be randomized to receive either 1064nm alone or 1064nm \& 585nm combination treatment. Each subject will receive up to 3 treatments at monthly intervals (±4 days). Follow-up visits will take place at 1, 3, and 6 months following the last treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | PiQo4 | PiQo4 Laser System for treatment of Melasma |
Timeline
- Start date
- 2018-07-02
- Primary completion
- 2019-08-08
- Completion
- 2019-08-08
- First posted
- 2018-06-21
- Last updated
- 2019-12-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03565341. Inclusion in this directory is not an endorsement.